Varenicline: a new pharmacotherapy for smoking cessation in primary care practice

References

• Esson LL, Leeder, SR. The millennium development goals and tobacco control: an opportunity for global partnership. Geneva: World Health Organization; 2004.
   Google Scholar
• MacKay, Crofton J. editors. Tobacco and the developing world. London: Royal Society of Medicine Press; 1996.
   Google Scholar
• Curry SJ, Keller PA, Orleans CT, Fiore MC. The role of health care systems in increased tobacco cessation. Annu Rev Public Health 2008; 29: 411–28.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24(1): 51–61.
   PubMed Web of Science ®Google Scholar
• Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
   Google Scholar
• Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103(1): 146–54.
   PubMed Web of Science ®Google Scholar
• Terres W, Becker P, Rosenberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994; 97(3): 242–9.
   PubMed Web of Science ®Google Scholar
• Taylor DH Jr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health 2002; 92(6): 990–6.
   PubMed Web of Science ®Google Scholar
• Tonnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29(2): 390–417.
   PubMed Web of Science ®Google Scholar
• Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002; 3(8): 461–9.
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors [see comment]. BMJ 2004; 328(7455): 1519.
   PubMed Web of Science ®Google Scholar
• McRobbie H, Bullen C, Glover M, Whittaker R, Wallace-Bell M, Fraser T. New Zealand smoking cessation guidelines. N Z Med J 2008; 121(1276): 57–70.
   PubMedGoogle Scholar
• Le Foll B, George TP. Treatment of tobacco dependence: integrating recent progress into practice. Canadian Medical Association Journal 2007; 177(11): 1373–80.
   Web of Science ®Google Scholar
• Siu EC, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 2007; 47: 541–64.
   PubMed Web of Science ®Google Scholar
• Le Foll B, Goldberg SR, Sokoloff P. Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Investig Drugs 2007; 16(1): 45–57.
   PubMed Web of Science ®Google Scholar
• Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev 2006; 25(1): 59–71.
   PubMed Web of Science ®Google Scholar
• Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004; 9(1): 39–53.
   PubMedGoogle Scholar
• Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29(6): 1040–56.
   PubMed Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29(6): 1027–39.
   PubMed Web of Science ®Google Scholar
• Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009; 14(3): 384–92.
   PubMed Web of Science ®Google Scholar
• Jimenez-RuizC, BerlinI, Hering T. Varenicline: anovelpharmacotherapy for smoking cessation. Drugs 2009; 69(10): 1319–38.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008; 83(4): 531–41.
   PubMed Web of Science ®Google Scholar
• Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug & Alcohol Dependence 1993; 33(1): 23–9.
   PubMed Web of Science ®Google Scholar
• Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166(15): 1571–7.
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008; 121(4 Suppl 1): S32–42.
   PubMed Web of Science ®Google Scholar
• Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 164(8): 1269.
   PubMed Web of Science ®Google Scholar
• Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 2008; 299(10): 1121–2.
   PubMed Web of Science ®Google Scholar
• Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008; 24(7): 1931–41.
   PubMed Web of Science ®Google Scholar
• Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805.
   PubMed Web of Science ®Google Scholar
• Moore TJ, Furberg CD. Varenicline and suicide. Risk of psychiatric side effects with varenicline. BMJ 2009; 339: b4964.
   PubMed Web of Science ®Google Scholar
• Yan J. FDA warns of suicide risk for more medications. Psychiatric News 2008; 43(5): 23.
   Google Scholar
• Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007; 164(8): 1269–70.
   PubMed Web of Science ®Google Scholar
• Morstad AE, Kutscher EC, Kennedy WK, Carnahan RM. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother 2008; 42(2): 288–9.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV. 4, illustrated ed: American Psychiatric Association, 1994
   Google Scholar
• Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63(8): 717–24.
   PubMed Web of Science ®Google Scholar
• Bolin K, Wilson K, Benhaddi H, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries. Eur J Public Health 2009; 19(6): 650–4.
   PubMed Web of Science ®Google Scholar
• Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009; 32(6): 499–507.
   PubMed Web of Science ®Google Scholar